RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis

RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis

On July 16, 2021, we hosted an online RNAi Roundtable to review the progress with patisiran and vutrisiran, in development for the treatment of transthyretin-mediated amyloidosis.

Access the replay
View the presentation

Rena Denoncourt
Vice President, ATTR Amyloidosis Franchise Lead

Dawn
Caregiver and hATTR Amyloidosis Patient

Rebecca Shilling, M.D.
Director, Clinical Research

Patrick Jay, M.D.
Director, Clinical Research

Mat Maurer, M.D.
Columbia University Medical Center, Arnold and Arlene Goldstein Professor of Cardiology

John Vest, M.D.
Vice President, Clinical Research